In 2023, China implemented a range of drug regulations, encompassing various aspects such as active pharmaceutical ingredient (API) registration renewal, the outsourcing of manufacturing by marketing authorization holders (MAHs), and drug inspection, among others.

Furthermore, China conducted the bidding process for its 9th national volume-based procurement (VBP) and engaged in price negotiations for the 2023 edition of the National Reimbursement Drug List (NRDL). These initiatives significantly influenced the pricing and market accessibility of pharmaceutical products. 

We are hosting this webinar to provide comprehensive coverage of the significant regulatory updates throughout the year. Our goal is to ensure pharma companies are well-informed when devising strategies to enter and expand within the Chinese market.

1. China’s Drug Regulatory System

1.1 Main regulators

1.2 Major laws and regulations

2. 2023 Regulatory Updates

2.1 Regulations

2.2 Policies

• The 9th National Volume-based Procurement (VBP)

• 2023 National Reimbursement Drug List (NRDL)

• List of Pediatric Drugs Encouraged for Development and Application

And more…

Notes:

• Feel free to reach out to us with any questions you may have before, during, or after the webinar.

• Following the conclusion of the webinar, we will upload the resources, including slides and recording, to this webpage.

• In the event that you are unable to attend the live webinar, we still encourage you to register. Rest assured that we will promptly send you the link for downloading the resources as soon as they become available.